Terumo BCT builds the machines and disposables that sit at the critical junction of blood processing and cellular therapy. The threat surface here is real and literal: devices like the Spectra Optia Apheresis System treat sickle cell disease, and the Quantum Flex Cell Expansion System is in the loop for CAR-T therapies. This is medtech where a compromised system isn't an inconvenience - it's a patient safety incident. Operations span 130+ countries, with headquarters in Lakewood, Colorado and more than 8,000 associates globally.
For cybersecurity, that means the attack surface extends from connected medical devices and manufacturing systems to global IT infrastructure handling sensitive health data. The regulatory environment is dense - FDA, HIPAA, international equivalents - and the engineering domains are specialized: blood component collection, therapeutic apheresis, and cellular therapy tech. Security teams here aren't securing a SaaS product; they're defending systems that directly interface with clinical workflows and patient outcomes.
The company operates across hematology, oncology, and broader healthcare verticals, with partnerships including The Leukemia & Lymphoma Society. The work is technical and the stakes are embodied - this is not a company where security can be an afterthought bolted onto engineering cycles.
